| Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae -> Monitor Keywords |
|
|
 
Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridaeRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), O-glycosideBicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20050267048, Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae. Brief Patent Description - Full Patent Description - Patent Application Claims
BACKGROUND OF THE INVENTION [0001] The invention relates generally to compounds active against viral diseases and, more specifically to bicyclic carbohydrate compounds that are useful in the prophylaxis and treatment of diseases caused by the alphaherpesvirina cytomegalovirus. [0002] Cytomegalovirus (CMV) is the largest human herpes virus, and there is only one serotype. As with animal CMVs it is species specific; humans are the natural hosts and animal CMVs do not infect humans. The name refers to the multinucleated cells, which together with the intranuclear inclusions, are characteristic responses to infection with this virus. Transmission is via saliva, and CMVs were originally called `salivary gland` viruses. Urine is an additional source of infection in children, and in infected pregnant women the virus can spread via the blood to the placenta and fetus. Semen and cervical secretions may also contain virus and it can therefore be spread by sexual contact. It is often present in milk in small quantities, but this is of doubtful significance in transmission. In hospitals it can be transmitted by blood transfusion and organ transplants. CMV infections are often asymptomatic, but can reactivate and cause disease when CMI (cell mediated immune response) defenses are impaired. After clinical silent infection of unknown cells in the upper respiratory tract, CMV spreads locally to lymphoid tissues and then systemically in circulating lymphocytes and monocytes to involve lymph nodes and the spleen. The infection then localizes in epithelial cells in salivary glands and kidney tubules, and in cervix, testes and epididymis, from where the virus is shed to the outside world (Table 1). 1TABLE 1 Cytomegalovirus infections Site of infection Result Comment Salivary glands Salivary transmission Importance of kissing and contaminated hands Tubular Virus in urine Probable role of transmission epithelium of Sexual transmission Up to 10.sup.7 infectious doses/ml kidney Cervix/ of semen in an acutely Testis/ infected male epididymis Lymphocytes/ Virus spread through Probable site of persistent Macrophages body via infected cells infection Mononucleosis may occur Immunosuppressive effect Placenta/Fetus Congenital abnormalities Greatest damage in fetus after primary maternal infection rather than reactivation [0003] Infected cells may be multinucleated or bear intranuclear inclusions, but pathologic changes are minor and infection is generally asymptomatic. In young adults, a glandular fever type illness can occur, but without heterophil antibodies. There is fever and lethargy, and abnormal lymphocytes and mononucleosis in blood smears. The virus inhibits T cell responses and there is a temporary reduction in their immune reactivity to other antigens. Although specific antibodies and CMI responses are generated, these fail to clear the virus, which often continues to be shed in saliva and urine for many months. The infection is, however, eventually controlled by CMI mechanisms, although infected cells remain in the body throughout life and can be a source of reactivation and disease when CMI defenses are impaired. CMV owes its success in our species to its ability to evade immune defenses (Cann A. J. (1997) Principles of Molecular Virology. Second Edition. Academic Press, San Diego, pp. 65-67; Mims C., Playfair J., Roitt I., Wakelin D. and Williams R. (1998) Medicinal Microbiology. Second Edition. Mosby International Limited, pp.347-348). [0004] Ganciclovir is an anti-CMV drug that works by inhibiting CMV's DNA polymerase enzyme. It can prevent CMV from reproducing and infecting new cells, but it cannot eliminate it from the body. Ganciclovir is manufactured by Roche under the trade name Cymevene. In the US its trade name is Cytovene. Ganciclovir now comes in several formulations: oral, intravenous and intravitreal (into the eye). It is either given intravenously on a long-term basis through a catheter or in a pill form. In the case of administration by catheter, one end of a tube is surgically inserted into a large vein in the chest, the other end of the tube remains outside the chest or has an injectable port just under the skin. Although slightly less efficient, an oral form of ganciclovir is also approved by the FDA for prevention and maintenance treatment of CMV. [0005] Unfortunately, ganciclovir also suppresses bone-marrow production of the white blood cells called neutrophils. This condition is called neutropenia. People taking ganciclovir require close monitoring to ensure blood disorders are promptly detected. It can also harm the kidneys, reduce testosterone levels, and cause nausea, vomiting, diarrhea and rash. More than 10% of IV ganciclovir recipients have to stop treatment because of these side effects. In addition, the development of strains of CMV that are resistant to ganciclovir has been reported. These do not seem to develop any faster with oral ganciclovir than with the intravenous formulation (www.aidsmap.com). [0006] Alternative compounds with activity against herpes viruses such as cytomegalovirus are needed. SUMMARY OF THE INVENTION [0007] The invention consists of the novel bicyclic carbohydrates the generic structure of which is: 2 [0008] wherein R.sub.1 is either -Bn or -Ph; R.sub.2 and R.sub.3 are either -alkyl, -aryl, -allyl, or --H; R.sub.4 and R.sub.5 form a ring and are either --CH(Ph)- or --CH(aryl)- and X is either O, N or S, herein referred to as Formula A. Compounds of Formula A have activity against infections caused by the cytomegalovirus. The invention also includes analogs, prodrugs and pharmaceutically acceptable salts thereof, together with pharmaceutical compositions for the prophylaxis and treatment of diseases caused by infections of alphaherpesvirinae and particularly cytomegalovirus. BRIEF DESCRIPTION OF THE DRAWINGS [0009] FIG. 1 is a chemical structure of the bicyclic carbohydrates of the present invention and designated Formula A. [0010] FIG. 2 is a diagrammatic representation of the activity of ganciclovir in cells that are non-infected and cells that are infected with herpes virus. [0011] FIG. 3 is a diagrammatic representation of the scheme of synthesis of Compound A1. [0012] FIG. 4 is a diagrammatic representation of the scheme of synthesis of Compound A2. [0013] FIG. 5 is a diagrammatic representation of the scheme of synthesis of Compound A3. [0014] FIG. 6 is a diagrammatic representation of the scheme of synthesis of Compound A4. [0015] FIG. 7 is a diagrammatic representation of the scheme of synthesis of Compound A5. [0016] FIG. 8 is a diagrammatic representation of the scheme of synthesis of Compounds A6 and A7. DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT [0017] The inventive compounds may be used in their native form or as salts. In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compounds as salts may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, acetate ascorbate, benzoate, citrate, etoglutarate, glycerophosphate, malonate, methanesulfonate, succinate, and tartarate. Suitable inorganic salts may also be formed, including bicarbonate, carbonate, hydrochloride, nitrate, and sulfate, salts. [0018] Compounds of the present invention can conveniently be administered in a pharmaceutical composition containing the compound in combination with a suitable excipient, the composition being useful in combating viral infections. Depending on whether the preparation is used to treat internal or external viral infections, the compounds and compositions of the present invention can be administered parenterally, topically, intravaginally, orally, or rectally. [0019] For parenteral administration, solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Continue reading about Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae... Full patent description for Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae or other areas of interest. ### Previous Patent Application: Anti-hypercholesterolemic compounds Next Patent Application: Antineoplastic and anti-hiv conjugates of steroid acid and nucleosides Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae patent info. IP-related news and info Results in 0.32186 seconds Other interesting Feshpatents.com categories: Computers: Graphics , I/O , Processors , Dyn. Storage , Static Storage , Printers 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
